Trillium Therapeutics Inc. (TRIL)
(Delayed Data from NSDQ)
$0.58 USD
+0.01 (1.99%)
Updated May 3, 2019 03:59 PM ET
After-Market: $0.58 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGMBrokerage Reports
0 items in cart
[TRIL]
Reports for Purchase
Showing records 1 - 20 ( 54 total )
Industry: Medical - Drugs
Industry: Medical - Drugs
Industry: Medical - Drugs
Pfizer Agrees to Acquire Rest of Trillium; Downgrade to Neutral with $18.50 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Industry: Medical - Drugs
Industry: Medical - Drugs
Multiple Study Initiations in 2021; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Industry: Medical - Drugs
More Monotx Responses-Wait Begins for Combo Results
Provider: Bloom Burton & Company
Analyst: MARTIN D
Industry: Medical - Drugs
Multiple Shots on Goal for TTI-622 and TTI-621; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Industry: Medical - Drugs
Expecting Clarity on Clinical Development at R&D Day; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Industry: Medical - Drugs
Industry: Medical - Drugs
Industry: Medical - Drugs
Industry: Medical - Drugs
No Surprises at ASH; R&D Day Planned; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Industry: Medical - Drugs
Updated results for its TTI-622 monotherapy phase 1 trial
Provider: Bloom Burton & Company
Analyst: MARTIN D
Industry: Medical - Drugs
Clinical Updates Expected at ASH; Higher $22PT; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Industry: Medical - Drugs
Promising Clinical Updates; Pfizer Investment Could Lead to Opportunities; Upgrade to Buy With $16.50 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Industry: Medical - Drugs
TTI-622 Continues to Surprise on the Upside; Pfizer Invests
Provider: Bloom Burton & Company
Analyst: MARTIN D
Industry: Medical - Drugs
TTI-622 Update at ASH Could Be an Inflection Point; Reiterate Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Industry: Medical - Drugs
Industry: Medical - Drugs
Eyes on TTI-622 Update at ASCO; Reiterate Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Industry: Medical - Drugs
Dose Escalation Studies Progressing; Reiterate Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S